tbuckley/cabot-search huggingface dataset:
Abstract 14815: Impact of Fluctuations in Glucose Levels on Vascular Endothelial Dysfunction in Non Diabetes Mellitus (DM) Patients with Coronary Artery Disease (CAD)
Authors: Tomonori Akasaka, Seiji Hokimoto, Noriaki Tabata, Kenji Sakamoto, Kenichi Tsujita, Sunao Kojima, Koichi Kaikita, Hisao Ogawa
Journal: Circulation (2014)

Background: Fluctuations in glucose levels give rise to inflammation and endothelial dysfunction by increasing oxidative stress. Mean amplitude of glycemic excursions (MAGE) is commonly used as a degree of fluctuations in glucose levels, and plays a significant role in vascular endothelial dysfunction in patient with diabetes mellitus (DM). Vascular endothelial dysfunction is associated with cardiovascular event risk. Thus, we examined the impact of MAGE on vascular endothelial dysfunction and clinical outcomes in non DM patients with CAD. Methods: We analyzed 22 non DM patients with CAD following percutaneous coronary intervention (PCI) during 12 months follow up, and assessed the relationship among MAGE, the level of high-sensitivity CRP (hs-CRP), and reactive hyperemia index (RHI) measured from RH-PAT (reactive hyperemia peripheral arterial tonometry). Cardiovascular events were cardiovascular death, myocardial infarction, stroke, unstable angina,and revascularization. Results: In clinical characteristics of total patients, age, HbA1c, average of blood glucose for 24 hour, and MAGE were 73ys, 5.93%, 121.5mg/dl, and 55.5mg/dl. MAGE correlated with hs-CRP (r=0.610; P=0.004) and RHI (r=–0.485; P=0.047), but not correlated with HbA1c, LDL cholesterol, HDL cholesterol, triglyceride, and systolic blood pressures. In short, high glycemic excursions (high MAGE) is associated with high inflammation (high hs-CRP) and vascular endothelial dysfunction (low RHI). When patients were classified into MAGE&lt;60mg/dl (normal glycemic excursions) and MAGE&gt;60mg/dl (high glycemic excursions), group of MAGE&gt;60mg/dl were significant higher in hs-CRP (0.251±0.301 vs 0.072±0.067mg/dl, P=0.048) and lower in RHI (0.392±0.193 vs 0.834±0.316, P=0.008) than group of MAGE&lt;60mg/dl. Multivariate analysis for vascular endothelial dysfunction identified MAGE as a predictive factor (OR13.3, 95%RI 1.069-166.4, P=0.044). Moreover, MAGE was an independent predictive factor for cardiovascular events (OR11.0, 95%RI 1.42-85.20, P=0.022) Conclusions: Fluctuations in glucose levels are associated with inflammation, endothelial dysfunction, and cardiovascular events risk in non DM patients with CAD.
Evolving role of growth factors in the renal response to acute and chronic disease.
Authors: L G Fine, M R Hammerman, H E Abboud
Journal: Journal of the American Society of Nephrology (1992)

The roles of growth factors in the pathogenesis of various forms of acute and chronic renal disease are largely putative. Nevertheless, there is a growing body of information that links specific growth factors to particular forms of renal injury. In all instances, it is supposed that such associations are not necessarily unique and that multiple cytokines probably interact to determine the pattern of injury or the regenerative response to such injury. Regeneration of tubular epithelium after acute tubular necrosis involves upregulation of the epidermal growth factor (EGF) receptor. Early studies of exogenously administered EGF indicate that the severity and duration of renal failure may be attenuated by this growth factor. Thus far, the observed responses have been limited and the role of EGF as a therapeutic agent requires more study. The mechanism of generation of tubulointerstitial injury in most forms of renal disease is difficult to understand. Early in vitro studies of growth factor production by tubular cells (in the absence of any infiltrating cells) indicate that platelet-derived growth factor produced by the medullary collecting duct is mitogenic for renal medullary fibroblasts, suggesting a paracrine growth system in this region of the kidney. Insulin-like growth factor I has also been shown to be produced by collecting duct cells. Its production is increased by EGF, and its association with certain forms of renal hypertrophy, i.e., diabetes and hypersomatotrophic states, implies its participation in the hypertrophic growth response. Platelet-derived growth factor is a potent mitogen for glomerular mesangial cells, and its production is regulated by a variety of cytokines.(ABSTRACT TRUNCATED AT 250 WORDS)
Phase I immunotherapy in women with metastatic breast cancer with activated T cells targeted with anti-CD3 x anti-Her2/<i>neu</i> bispecific antibody
Authors: L. G. Lum, Z. Al-Kadhimi, C. Skuba, R. Sandborg, R. Rathore, Q. Liu, J. P. Uberti, V. Ratanatharathorn
Journal: Journal of Clinical Oncology (2008)

3034 Background: Women with metastatic breast cancer (MBC) have limited treatment options. Nontoxic approaches to improve targeting and cytotoxicity directed at MBC are needed. Anti-CD3 activated T cells (ATC) can be expanded and retargeted (armed) with anti-CD3 x anti-Her2 bispecific antibody (HER2Bi). Preclinical studies showed that Her2Bi-armed ATC exhibit high levels of specific cytotoxicity, proliferate, and secrete cytokines/chemokines (Clin Canc Res 12:569, 2006). Methods: In a phase I trial using ATC armed with Her2Bi, 17 MBC (31–86 yrs) patients (pts) were treated with 8 infusions (twice/week) for 4 weeks with 5, 10, 20, and 40 billion armed ATC/dose to determine the maximum tolerated or technically feasible dose. T cells from leukopheresis were activated and expanded with anti-CD3/IL-2 for 14 days, harvested, armed with Her2Bi at 50 ng/106ATC, and cryopreserved. IL-2 (3 x 105 IU/m2/daily) and GM-CSF (250 μg/m2 twice/week) was given beginning 3 days prior to the 1st infusion and ending 1 week after the last infusion. Results: The toxicities are summarized in the Table. Restaging at 1 month revealed 1 pt who developed a PR, 9 pts with SD, 5 pts with PD. Two pts were not evaluable. Three of 5 with CA27–29 markers decreased their markers by 15–50%. In 4 patients with positive CEA markers, 2 reduced their CEA levels by >50% and 2 by >15–50%. In 5 pts with circulating Her2 receptors (Her2r), 2 decreased Her2r by >50% and 2 reduced their Her2 by >15–50%. The median follow-up was 14.9 mos for the HER2(3+) group and 15.7 mos for the HER2(0–2+) group. Median time to progression was 3 and 6 mos for the HER2(3+) and HER2 (0–2+) groups, respectively. In the HER2(3+) group, median overall survival was not been reached with median follow-up of 14.9 mos. The median survival for the HER2(0–2+) cohort is 21.3 mos. The median survival for all pts remains undefined. Conclusions: These data suggest that infusions of armed targeted T cells can be safely infused and may improve overall survival in women with MBC. Infusion Toxicities Grade I II III IV # Episodes Chills 0 4 36 0 40 Headache 0 3 14 1 17 Nausea/Vomiting 8 1 0 0 9 Fever 3 1 0 0 4 Hypotension 1 3 0 0 4 Hypertension * 0 0 0 1 1 Dyspnea 0 1 0 0 1 # Episodes/130 infusions; * hypertension associated with a subdural hematoma. 1 pt died of Digoxin toxicity Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Transtarget Transtarget Transtarget
The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents.
Authors: N. M. La-Beck, H. Wu, J. R. Infante, S. F. Jones, H. A. Burris, V. L. Keedy, H. Kodaira, S. Ikeda, R. K. Ramanathan, W. Zamboni
Journal: Journal of Clinical Oncology (2010)

e13003
Association Between Transient Newborn Hypoglycemia and Test Proficiency—Reply
Authors: Jeffrey R. Kaiser, Shasha Bai, Nahed O. ElHassan
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Treatment of malignant mesothelioma with epirubicin and ifosfamide: A phase II cooperative study
Authors: M.D. Magri, S. Foladore, A. Veronesi, C. Serra, M. Nicotra, M. Tommasi, G. Grandi, S. Monfardini, C. Bianchi
Journal: Annals of Oncology (1992)
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients (pts): An exploratory retrospective analysis.
Authors: Luigi Coltelli, Andrea Fontana, Guido Bocci, Andrea Camerini, Antonella Ferro, Marina Elena Cazzaniga, Virginia Casadei, Ilaria Pazzagli, Lorenzo Marcucci, Giacomo Allegrini, Sara Lucchesi, Eleonora Bona, Marco Scalese, Paola Orlandi, Federica Villa, Silvano Morini, Domenico Amoroso, Giada Arrighi, Mario Filidei, Alfredo Falcone
Journal: Journal of Clinical Oncology (2013)

1086 Background: Previous retrospective studies have attempted to identify a possible role of VEGF single nucleotide polymorphisms (SNPs) to predict BV efficacy in terms of OS and PFS in MBC pts with conflicting results (Schneider 2008, Grimaldi 2011, Lambrechts 2011). Methods: On the basis of these preliminary data, we decided to assess in a MBC population if different VEGF, VEGFR-2, IL-8, IL-6, HIF-1alfa, EPAS-1 and TSP-1 genotypes could predict first line BV + paclitaxel (P) response in terms both of OS and PFS. Analyses were performed on germline DNA obtained from blood samples. Fourteen polymorphisms were investigated by real-time PCR technique. Both single and combinations of SNPs were investigated. The multifactor dimensionality reduction (MDR) methodology was applied to identify a genetic interaction profile for PFS ( http://sourgeforge.net/projects/mdr/ ). Results: 102 pts have been enrolled from 8 Oncology Units. Main pts characteristics are: median age 59 years (range 32-81), ECOG-PS 0/1 in 78%/22%, hormone receptor positive 83%, previous adjuvant chemotherapy 68%, disease free interval (DFI) &lt; 12 months 27%. After a median follow up of 17.4 months (1.9-54.7), mPFS was 11.6 months (95% CI: 10.6-12.6) and mOS was 32.4 months (95% CI: 25.9-38.9). None of SNPs were individually associated with PFS. Conversely, a genetic interaction profile consisting of VEGFR-2 rs11133360 and IL-8 rs4073 was significantly associated with PFS. mPFS was 14 months (95% CI: 11.7-16.3) and 10.9 months (95% CI: 9.3-12.4) for the favorable and unfavorable genetic profile, respectively (HR=0.63, 95% CI: 0.4-0-99, p= 0.046). Furthermore, at the multivariate analysis hormone receptor positive (HR=0.22, 95% CI: 0.12-0-41, p&lt;0.0001), DFI &gt;12 months (HR= 0.4, 95% CI: 0.2-0.82, p= 0.011) and BV maintenance (HR=0.63, 95% CI: 0.25.0.71, p=0.001) were significantly associated with a better PFS. Conclusions: Genetic interaction between VEGFR-2 rs11133360 and IL-8 rs4073 polymorphisms could predict BV response in terms of PFS. With a longer follow-up correlations with OS will be investigated. Prospective study is planned. Study supported by the non-profit foundation F.A.R.O.
Annals On Being a Doctor Story Slam - Speaking Out
Authors: Lisa A. Mandl
Journal: Annals of Internal Medicine (2016)

Web Exclusives19 January 2016Annals On Being a Doctor Story Slam - Speaking OutFREELisa A. Mandl, MD, MPHLisa A. Mandl, MD, MPHFrom the Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/V15-0018 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals On Being a Doctor Story Slam - Speaking Out This story, "Speaking Out," by Dr. Lisa A. Mandl, is from the Annals On Being a Doctor Story Slam held on 18 November 2015 in Philadelphia, with support from the Josiah Macy Jr. Foundation. (Duration 5:08)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals On Being a Doctor Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Alan T. Kaell MD FACP FACR Clinical Professor of Medicine SUNY SB (Voluntary)22 February 2017 Sharing in a Non-Judgemental Thoughtful Manner Dr Mandl's story exudes the evolution and development of health care providers' authentic experience of active listening skill's. The self reflection reinforces the importance to both engaging the patient in speaking out and in the contemplation of both the documentation and what, if anything, to do with the knowledge of information gained.Thanks for sharing ! Author, Article, and Disclosure InformationAffiliations: From the Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.Note: This story is from the Annals On Being a Doctor Story Slam held on 18 November 2015 in Philadelphia, with support from the Josiah Macy Jr. Foundation.Corresponding Author: Lisa A. Mandl, MD, MPH, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY 10024; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 January 2016Volume 164, Issue 2Page: SS7KeywordsHospital medicineSurgery ePublished: 19 January 2016 Issue Published: 19 January 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.Loading ...
Alemtuzumab (ALZ) as treatment for severe paraneoplastic pemphigus (PNP) associated to B-cell chronic lymphocytic leukemia (CLL)
Authors: R. B. Nielsen, T. Steinicke, N. A. Peterslund, T. Hohwy, K. Bang, F. D′amore
Journal: Journal of Clinical Oncology (2006)

16520 Background: ALZ is a monoclonal antibody used in the treatment of CLL. PNP is a mucocutaneous disease frequently associated with B-cell malignancies. PNP is often refractory to immunosuppressive drugs and is frequently fatal. Methods: We here report two cases, where ALZ induced a complete and sustained remission of both PNP and CLL and one case with a significant remission of PNP alone. Results: A 68-year old male with a 4-year CLL history developed blisters and ulcers on the extremities and trunk and severe stomatitis. Despite steroids, fludarabine, cyclophosphamide, ciclosporin A, and azathioprin, PNP exacerbated. A standard 12-weeks ALZ schedule was initiated. PNP lesions gradually regressed under the last weeks of treatment and resolved completely a few weeks later. A bone marrow biopsy showed morphologic and flowcytometric signs of remission. Now, 30 months after ALZ, the patient’s PNP and CLL are still in remission. Almost a year after this first case, a 77-year old male with a 3-year CLL history, presented with severe mucocutaneous lesions of the lips, oro-esophageal cavity, penis and extremities. PNP was diagnosed and a standard 12-weeks ALZ schedule was initiated. The lesions began to regress during the last weeks of treatment and normalized within the subsequent 8 weeks. This remission had a duration of 1½ year, after which the patient was hospitalized with evidence of PNP relapse. He is currently undergoing renewed ALZ therapy. An 80-year old female with a 4-year history of CLL, showed signs of disease progression after 2 treatment-free years.She then developed mucocutaneous lesions diagnosed as PNP. In spite of cytoreductive treatment, both PNP and CLL progressed and ALZ was given. All PNP lesions promptly disappeared, but recurred already 2 weeks after discontinuation of ALZ. Concomitantly, the patient developed a Legionella pneumonia. In spite of erythromycin, she deteriorated clinically and died one month later. At autopsy, marked CLL involvement of bone marrow and retroperitoneal lymph nodes was found. Conclusion: ALZ is an effective treatment in severe CLL-associated PNP. The observed duration of response was variable. A larger number of patient observations is necessary in order to identify patterns of response. No significant financial relationships to disclose.
Preferences (PREF) over time of patients (pts) with ovarian cancer (OVCA) receiving conventional dose platinum-based chemotherapy (CDCT)
Authors: C. C. Sun, M. L. Donato, J. K. Wolf, C. B. Weaver, M. A. Fitzgerald, D. M. Gershenson, D. C. Bodurka
Journal: Journal of Clinical Oncology (2004)

8227 Background: Previously we reported the PREFs of pts with OVCA on phase II studies of high-dose chemotherapy (HDCT) and stem cell transplant for side effects (SEs) of chemotherapy (CT). To determine the impact of frontline CT, we assessed PREFs of pts with newly diagnosed OVCA receiving platinum-based CDCT. Methods: PREFs were assessed for 12 SEs of CT at 2 points in time using a modified time trade-off (TTO) method. Time 1 (T1) was prior to cycle #1 of CDCT, Time 2 (T2) was conducted after cycle #5. Pts were asked to choose 1 of 2 hypothetical CTs with equal clinical effectiveness, both requiring 10 days of hospitalization. CHEMO1 involved only the specific SE in question at a severe grade of toxicity. CHEMO2 involved multiple SEs but at mild to moderate grade of toxicity. If CHEMO1 was chosen, the number of days required for CHEMO2 was systematically decreased until the pt said that the 2 CTs were equivalent or that CHEMO2 was preferable. PREFs were converted to scores ranging from 0=least favorable to 1=most favorable. Symptoms were assessed longitudinally via the Memorial Symptom Assessment Scale (MSAS). Data were analyzed using Wilcoxon signed rank test. Results: To date, 17 pts have completed T1 and T2. All patients were had surgical staging and were dispositioned to 6 cycles of platinum-based CT. The median age was 58.9 years. Median time from T1 to T2 was 5.2 months. Compared to T1, PREFs were less favorable for nausea (T1=.90, T2=.65, p=.065), mucositis (T1=.90, T2=.60), dysuria (T1=.80, T2=.70), ototoxicity (T1=.90, T2=.70), and hepatotoxicity (T1=.80, T2=0.0). After having received 5 cycles of CDCT, pts were willing to accept up to 8 additional days of CHEMO2 in order to avoid CHEMO1 when the SEs listed above were involved. From T1 to T2, pts also reported increased symptom distress levels for nausea, alopecia (p=.04), fatigue, and neuropathy. Conclusions: PREFs of pts receiving CDCT appear to follow the same trend as our previous study of PREFs of pts on HDCT. PREFs for certain SEs may be negatively influenced by the overall treatment process, irrespective of whether pts actually experienced these SEs. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck & Co.; MGI Pharma MGI Pharma Merck & Co.; MGI Pharma
Single Cell Analysis Of Protein Phosphorylation In Chronic Myeloid Leukemia Treated With Dasatinib, Eltrombopag, and Pegfilgrastim
Authors: Bjorn T Gjertsen, Stein E Gullaksen, Jorn Skavland, Mihaela Lucia Popa, Roald Lindas, Randi Hovland, Klaus Beiske, Henrik Hjorth-Hansen, Emmet McCormack
Journal: Blood (2013)
Expression of thymidylate synthase in primary colorectal carcinoma and their corresponding metastases
Authors: R. Bendardaf, A. Elzagheld, R. Ristamäki, K. Syrjänen, S. Pyrhonen
Journal: Journal of Clinical Oncology (2006)

13587 Objective: Thymidylate synthase (TS) is the rate-limiting enzyme in the synthesis of pyrimidine nucleotides required for DNA synthesis and is a critical target for fluoropyrimidines, which are widely used in the treatment of gastrointestinal tumours. Tumour TS expression was analysed in a series of 39 patients diagnosed and treated for Duke’s B, C and D colorectal cancer between January 1996 and August 2003 to investigate the role of TS in the development of metastatic phenotype in CRC. Methods: TS expression was determined immunohistochemically in 39 paraffin-embedded primary and metastatic tumour sections and the overall staining index was calculated according to the intensity of the cytoplasmic staining (0, 1, 2, 3) and the fraction of the corresponding tumour cells in the sample. Results: Tumours were classified as showing either lower or higher TS expression, i.e. below- or above the mean. In 29/39 (74.3%) pairs, the primary tumours and their metastases are concordant. In 10 out of 39 (25.7%) discordant pairs, TS expression was high in the primary tumours and low in the metastasis in 9/10 cases, and opposite in the remaining one case. Using the absolute staining index values, TS expression in the primary tumours and in the metastases was also significantly correlated (Pearson R=0.501, p=0.001). Conclusion: Between the paired primary tumours and distant metastatic lesion, the TS expression is in the majority higher in primary tumours compared to the metastasis and more concordant cases showed compared to discordant cases and in 9/10 discordant cases, TS expression in the primary tumours was above the mean and below the mean in their corresponding metastases compare to only one case showing the opposite pattern. No significant financial relationships to disclose.
Abstract 14760: Apolipoprotein (apo) Mimetic Peptides ATI-5261 and CS-6253 Induce ABCA1/ABCG1 Mediated HDL Formation and Maturation in a Process Including ABCA1 Oligomerization and LCAT in Way Similar to apoA-I
Authors: Anouar Hafiane, John K Bielicki, Jan O Johansson, Jacques Genest
Journal: Circulation (2013)

Two novel (26-AA) apolipoprotein (apo) mimetic peptides ATI-5261 and CS-6253 were studied in vitro for their ability to interact with ABCA1 and ABCG1 and to generate functional HDL-like particles. ...